BPC-157 vs Sermorelin: Comparing the Indexed Record
BPC-157 and Sermorelin are routinely cross-referenced by researchers scoping a literature review. The two records are not equivalent.
Compound profiles
BPC-157 in the indexed record
The literature on BPC-157 is a moderate body of work: 228 PubMed-indexed records, alongside 4 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Altern Ther Health Med, Cell Tissue Res, Curr Rev Musculoskelet Med, spanning 2019–2025.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain — Altern Ther Health Med, 2021. PMID: 34324435
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS J, 2025. PMID: 40756949
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing — Cell Tissue Res, 2019. PMID: 30915550
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review — Pharmaceuticals (Basel), 2025. PMID: 40005999
Sermorelin in the indexed record
Indexed output for Sermorelin stands at 332 records, a moderate literature, alongside 42 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Clin Interv Aging, Drug Test Anal, J Am Acad Orthop Surg Glob Res Rev, spanning 2006–2026.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal, 2021. PMID: 34665524
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? — Clin Interv Aging, 2006. PMID: 18046908
Classification and why it matters
BPC-157 and Sermorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for BPC-157 describes conditions validated for BPC-157: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Sermorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | BPC-157 | Sermorelin |
|---|---|---|
| PubMed indexed records | 228 | 332 |
| Registered studies (ClinicalTrials.gov) | 4 | 42 |
| Literature depth | Moderate | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. Sermorelin carries 104 more indexed records than BPC-157, which means published methodology, characterisation data and replication attempts are more readily located for Sermorelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (4 vs 42) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Documentation standards
Identity and purity are separate claims requiring separate methods. A purity percentage quoted without the analytical method behind it, or a certificate with no lot reference, is a documentation gap rather than verification.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Selecting between them for a study design
BPC-157 and Sermorelin are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Sermorelin) generally offers more methodological precedent.
Frequently asked questions
Which of BPC-157 or Sermorelin has more published research?
Sermorelin, with 332 indexed PubMed records against 228.
Are BPC-157 and Sermorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 228 indexed records for BPC-157 and 332 for Sermorelin.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- BPC-157 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.